Search
People
Professor Jonathan Carapetis AMInstitute Director; Head, Strep A Translation; Co-Founder of REACH
As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story
News & Events
Rheumatic Heart Disease Endgame Strategy: what does it mean to community?Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).
End RHD CRE News & Events
Research
Status of research and development of vaccines for Streptococcus pyogenesVaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development
Research
Screening for rheumatic heart disease: Quality and agreement of focused cardiac ultrasound by briefly trained health workersAfter brief training, health workers with no prior experience in echocardiography can obtain adequate quality images and make a reliable assessment
Research
Controlling acute rheumatic fever and rheumatic heart disease in developing countries: Are we getting closer?Improved opportunities for the primary prevention of ARF now exist, because of point-of-care antigen tests for Streptococcus pyogenes, and clinical decision...
Research
Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...
Research
A conceptual framework for comprehensive rheumatic heart disease control programsThe World Health Organization, World Heart Federation, and other organizations recommend comprehensive control programs for rheumatic fever (RF) and...
News & Events
Urgent action needed to stop 500 preventable deathsA new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken.